Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Oncology drugs
Biotech
Cullinan puts kibosh on 2 cancer assets amid autoimmune refocus
The move balances the number of candidates in Cullinan’s pipeline, which now encompasses four named assets across autoimmune and cancer indications.
Fraiser Kansteiner
Nov 6, 2025 1:26pm
Karyopharm lays off 20% of staffers amid hunt for alternatives
Jul 11, 2025 11:02am
TegMine bags tech from OBI to help fuel ADC ambitions
Jun 6, 2025 10:00am
Ascletis slashes funds for former core programs in obesity pivot
Mar 26, 2025 10:00am
Pyxis' shares fall on lukewarm early ADC results in solid tumors
Nov 21, 2024 2:30pm
AstraZeneca pays $19M for Nona's preclinical cancer antibodies
May 23, 2024 5:58am
